特朗普宣布与毒品贩子交易, 从2026年开始扩大肥胖药品、降低成本及扩大医疗保险覆盖面。 Trump announces deal with drugmakers to expand access to obesity meds, lower costs, and extend Medicare coverage starting 2026.

Trump于2025年11月6日宣布, 与Eli Lilly 和Novo Nordisk达成新协议, 扩大肥胖药品Zepbound和Wegovy的获取途径, 包括从2026年开始扩大医保覆盖面, 并推出较低成本选项, Trump announced on November 6, 2025, a new agreement with Eli Lilly and Novo Nordisk to expand access to obesity drugs Zepbound and Wegovy, including extending Medicare coverage starting in 2026 and introducing lower-cost options, such as a potential $149 monthly price for new pill versions. 作为降低处方药价格和解决国家肥胖症危机的更广泛努力的一部分,这项交易旨在降低自付成本和改善供应量,特别是未投保病人的供应量。 The deal aims to reduce out-of-pocket costs and improve availability, particularly for uninsured patients, as part of broader efforts to lower prescription drug prices and address the nation’s obesity crisis. 虽然没有充分披露具体的定价细节和推出时间表,但行政当局强调,这一举措将提高数百万人的健康成果。 While specific pricing details and rollout timelines were not fully disclosed, the administration emphasized the initiative would enhance health outcomes for millions.